Novartis NVS Under Fire After Triple Drug Disaster

Artisan Partners is demanding a Novartis board overhaul and M&A strategy reset after three consecutive clinical failures erased roughly $30 billion in market value, with NVS stock staging a tentative 1.3% recovery Thursday.

Lead

Novartis AG (NVS) is facing its most acute shareholder rebellion in years after a cascade of late-stage clinical failures stripped approximately $30 billion -- roughly CHF 24-26 billion -- from the Swiss pharmaceutical giant's market capitalization. Artisan Partners, one of the company's most prominent institutional shareholders, went public Thursday with demands for a board-level shake-up and a fundamental rethink of the company's acquisition strategy. NVS shares, which plunged 12.77% on September 8 in one of the largest single-session declines on record for the company, clawed back 1.3% to CHF 113.14 on September 10 as investors assessed the damage.

What Triggered the Selloff?

Three distinct clinical failures in rapid succession erased investor confidence in Novartis's pipeline. Del-desiran, a muscle-wasting therapy acquired through the $12 billion purchase of Avidity Biosciences in 2025, failed to beat placebo on its primary endpoint -- video hand opening time -- in the Phase 3 HARBOR trial enrolling roughly 150 patients with myotonic dystrophy type 1. The drug showed some secondary clinical activity but fell short of the threshold required to advance toward regulatory submission.

Separately, pelacarsen, a Lp(a)-lowering cardiovascular therapy developed alongside Ionis Pharmaceuticals, failed its 8,323-patient Phase 3 Lp(a)HORIZON study, which had targeted reduction in cardiovascular death, heart attack, and stroke. Despite successfully lowering Lp(a) levels, the drug produced no corresponding reduction in hard clinical outcomes -- eliminating what had been projected as a $4-5 billion peak annual sales opportunity. Novartis also paused eight clinical trials of rap-cel, a cell therapy, following three patient deaths.

Why Did Artisan Partners Demand a Board Shake-Up?

The string of failures focused investor attention not just on science, but on boardroom governance. David Samra, managing director at Artisan Partners and founding partner of the firm's International Value Group, argued publicly that successive Novartis chairmen had failed to exercise adequate oversight of the company's acquisitions. Samra described the M&A function as "uninspiring at best," and specifically cited the Avidity Biosciences deal as a case study in insufficient due diligence discipline. His call for board-level change represents a significant escalation of investor pressure on CEO Vas Narasimhan, who has presided over an aggressive but increasingly costly deal-driven pipeline strategy.

The criticism arrives at a structurally precarious moment. Novartis faces what Narasimhan has called the steepest patent cliff in the company's history, with blockbuster heart-failure drug Entresto losing key exclusivities. The three pipeline failures collectively undercut the thesis that acquired and internally developed assets would offset the Entresto revenue decline.

What Comes Next for Novartis's Pipeline?

Novartis now confronts a pipeline credibility gap that a single partnership or licensing deal is unlikely to close. The pelacarsen failure also carries broader biotech company sector implications: competing Lp(a)-targeting programs at Amgen (AMGN) and Eli Lilly (LLY) -- including olpasiran -- face elevated scrutiny from investors who may now question whether the entire therapeutic mechanism can translate Lp(a) reduction into clinical benefit.

The rap-cel trial pause adds a cell therapy dimension to the crisis and signals potential regulatory headwinds across Novartis's advanced modalities portfolio. Any path back to investor confidence requires demonstrating that remaining late-stage assets -- in areas including radioligand therapy and immunology -- can clear endpoints that the failed programs could not.

Strategic Context

The Artisan letter sharpens a debate that has simmered across big pharma: whether large-cap companies can generate positive returns from transformative M&A in an era of compressed timelines and elevated trial costs. The $12 billion Avidity acquisition, announced and closed within roughly a year of the asset's Phase 2 readout, is now being scrutinized as emblematic of deal risk taken without sufficient board-level challenge. Artisan's public posture raises the prospect of a proxy contest if management and the board do not respond with concrete governance changes ahead of the next annual meeting.

Outlook

Novartis shares remain down more than 10% from pre-September-8 levels. The board has not yet responded publicly to Artisan Partners' demands. Near-term catalysts include any formal statement from the chairmanship addressing governance structure, and data readouts from the radioligand therapy program that management has positioned as the next major growth driver. Until Novartis can demonstrate that its remaining late-stage assets are on solid clinical footing, institutional investors are likely to treat the recovery as a technical bounce rather than a fundamental turn.